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Clinical pharmacists in general practice: An initial evaluation of 51 
activity in one English primary care organisation 52 
 53 
ABSTRACT 54 
 55 
Objectives 56 
 57 
This aim of this research was to characterise the breadth and volume of activity 58 
conducted by clinical pharmacists in general practice in Dudley Clinical 59 
Commissioning Group (CCG), and to provide quantitative estimates of both the 60 
savings in general practitioner (GP) time and the financial savings attributable to 61 
such activity. 62 
 63 
Methods 64 
 65 
This descriptive observational study retrospectively analysed quantitative data 66 
collected by Dudley CCG concerning the activity of clinical pharmacists in GP 67 
practices during 2015. 68 
 69 
Key findings 70 
 71 
Over the nine month period for which data were available, the 5.4 whole time 72 
equivalent clinical pharmacists operating in GP practices within Dudley CCG 73 
identified 23,172 interventions. Ninety five per cent of the interventions identified 74 
were completed within the study period saving the CCG in excess of £1,000,000. 75 
Dudley clinical pharmacists in general practice 
4 
 
During the four months for which resource allocation data were available, the clinical 76 
pharmacists saved 628 GP appointments plus an additional 647 hours that GPs 77 
currently devote to medication review and the management of repeat prescribing. 78 
 79 
Conclusions 80 
 81 
This research suggests that clinical pharmacists in general practice in Dudley CCG 82 
are able to deliver clinical interventions efficiently and in high volume. In doing so, 83 
clinical pharmacists were able to generate considerable financial returns on 84 
investment. Further work is recommended to examine the effectiveness and cost-85 
effectiveness of clinical pharmacists in general practice in improving outcomes for 86 
patients. 87 
 88 
Keywords: clinical pharmacists, English National Health Service, general practice, 89 
general practitioners, primary care  90 
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INTRODUCTION 91 
 92 
In July 2015, National Health Service (NHS) England announced the launch of the 93 
‘Clinical Pharmacists in General Practice Pilot’ – a £15 million, three year initiative to 94 
fund, recruit and employ clinical pharmacists in General Practitioner (GP) 95 
surgeries.(1) The pilot intended to build upon the experiences of the limited number 96 
of GP surgeries, including surgeries within Dudley Clinical Commissioning Group 97 
(CCG), that already had clinical pharmacists in patient facing roles. The NHS 98 
England pilot would see pharmacists employed directly by GP surgeries to assist 99 
patients whilst easing GP workload and improving communication between general 100 
practice, hospitals and community pharmacists. In October 2015, the budget for the 101 
pilot was increased to £31 million with NHS England claiming that this would “part-102 
fund 403 new clinical pharmacist posts across 73 sites, covering 698 practices in 103 
England, supporting over 7 million patients”.(2,3) No surgeries within Dudley CCG 104 
were selected to be pilot sites.(4) 105 
 106 
Whilst interest in employing pharmacists in GP surgeries has increased markedly 107 
since the announcement of the NHS England pilot in July 2015, GP surgeries in 108 
Dudley have been utilising the skills of pharmacists in practice settings since 2002. 109 
As part of Dudley CCG’s Prescribing and Medicines Management Function, the CCG 110 
commissions the services of a team of practice-based pharmacists (PBPs) to 111 
promote safe, high quality and efficient prescribing within Dudley. The majority of 112 
these PBPs are independent prescribers1 and, in addition to a focus on the 113 
promotion of appropriate and cost-effective prescribing, the service provided by the 114 
PBPs has become increasingly clinically focussed. 115 
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  116 
While evidence of the effectiveness and cost-effectiveness of pharmacist activity in 117 
GP surgeries is generally lacking, a 2014 systematic review found that pharmacists 118 
deliver a range of interventions in general practice and these services often have 119 
beneficial impacts on outcomes in chronic diseases, principally in diabetes and 120 
cardiovascular disease, and in improving the quality of medication management 121 
services.(5) The majority of studies identified by this review were based in the United 122 
States with literature examining pharmacist activity in GP practices in England being 123 
sparse. However, two English-based randomised controlled trials suggest that 124 
pharmacist review of medication is effective at controlling prescribing 125 
expenditure.(6,7) Whilst the lack of evidence of effectiveness and cost-effectiveness 126 
of PBPs specifically is not surprising, given the relatively small number of pre-NHS 127 
England pilot PBPs and the comparatively recent announcement of the pilot, if the 128 
PBP model is to be accepted and embedded in general practice it is vital that 129 
thorough evaluation around effectiveness and cost-effectiveness is conducted.  130 
 131 
The aim of the research reported here was to characterise PBP activity in Dudley 132 
CCG. The research had the following objectives: 133 
 To describe the breadth and volume of interventions conducted by PBPs; and, 134 
 To provide quantitative estimates of both the savings in GP time and the 135 
financial savings attributable to PBP activity. 136 
 137 
METHODS 138 
 139 
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This descriptive observational study used quantitative data collected by the 140 
Pharmaceutical Public Health Team within Dudley CCG to analyse retrospectively 141 
PBP activity during 2015. Data covering the period from April to December 2015 142 
were collected by the Pharmaceutical Public Health Team within Dudley CCG. 143 
These activity data were routinely entered into a bespoke database by PBPs as per 144 
their work protocols. Data were extracted from the database in the form of 145 
spreadsheets which were then supplied to the authors. 146 
 147 
Fields included in the spreadsheets were: 148 
 The date that the activity took place. 149 
 The name of the GP practice where the activity took place. 150 
 A unique PBP identifier. 151 
 The type of activity undertaken. Activities were selected from a ‘dropdown’ list 152 
of 20 pre-coded options (these can be found in Table 1). The options were 153 
defined by service leads and training was provided to PBPs to promote the 154 
consistent and appropriate use of these options. Only one type of activity 155 
could be accepted per intervention. 156 
 The number of potential interventions identified by PBPs. 157 
 The number of potential interventions identified by PBPs which were 158 
subsequently completed. 159 
 Financial savings realised by the identified interventions which were 160 
completed. 161 
 162 
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Following an update to the data collection sheets to enable quantification of resource 163 
allocation, the spreadsheets for the months of September through December 2015 164 
included the following additional information: 165 
 The number of GP appointments avoided as a result of the identified 166 
interventions which were completed. 167 
 Amount of GP time saved by the involvement of the PBP in the review or 168 
reconciliation of medicines. 169 
 Amount of GP time saved by the involvement of the PBP in the management 170 
of repeat prescriptions. 171 
 172 
Data were manipulated and collated into one ‘master’ document in Microsoft Excel 173 
2013®. To this master document, the patient list size of each GP practice was 174 
added. This enabled per population comparisons between interventions at different 175 
GP practices. 176 
 177 
Data were analysed in Microsoft Excel®. Analysis was descriptive with assessment 178 
of central tendency and variability. Where available, data on the number of GP 179 
appointments saved, GP time saved by the involvement of PBPs in the review and 180 
reconciliation of medicines and GP time saved by the involvement of PBPs in the 181 
management of repeat prescriptions were exported from the master document and 182 
imported to a new document specifically for costs analysis. Unit costs for GP 183 
services were extracted from the Unit Costs of Health and Social Care 2015 – 184 
produced by the Personal Social Services Research Unit at the University of Kent – 185 
and added to these data to enable an estimation of financial savings resulting from 186 
the transference of GP activity to PBPs.(8)  187 
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 188 
Ethical approval for this work was not sought as the research was limited to 189 
secondary use of information previously collected in the course of normal care and 190 
the research involved no patient identifiable information.(9) The research was 191 
considered to be a ‘service evaluation’ by Dudley CCG.  192 
 193 
RESULTS 194 
 195 
Over the period April-December 2015, 23 PBPs (5.4 whole time equivalent) 196 
operating in 49 GP practices within Dudley CCG identified 23,172 interventions. The 197 
median number of interventions identified per month was 2,433 (interquartile range 198 
(IQR) ±1352) and the median number of interventions identified per GP practice was 199 
210 (IQR ±331). Of the identified interventions, 95% (n=21,954) were completed by 200 
practices within the study period. The number of interventions completed per 1,000 201 
listed patients varied considerably between practices ranging from 4 per 1,000 to 202 
1,131 per 1,000 listed patients (median = 43 (IQR±40))2. 203 
 204 
The type of interventions suggested by PBPs within Dudley CCG, the volume of 205 
these interventions identified and subsequently completed, and the savings 206 
attributable to these interventions can be seen in Table 1. Both the nature and 207 
volume of interventions varied markedly. The most common type of intervention 208 
completed was ‘medication reviews’ (n=4,413)3. The interventions completed yielded 209 
a total of £1,079,864 in savings (assuming activity was consistent throughout the 210 
calendar year, this would equate to an annual saving of £1,439,819). The type of 211 
activity yielding the highest financial saving (£355,491) was ‘planned changes to 212 
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medicines/ QIPP’ and the most productive type of intervention was the review of 213 
‘specials’ (yielding savings of £1,147 per completed intervention). 214 
 215 
Using data on the number of GP appointments and GP time saved for the months of 216 
September through December 2015, Table 2 provides information on the time and 217 
financial savings attributable to the transference of activity away from GPs to PBPs 218 
in Dudley (as opposed to the savings directly attributable to the interventions 219 
completed which are described above). Activities transferred from GPs to PBPs were 220 
patient consultations (ranging from consultations for minor ailments through to the 221 
management of long term conditions; with an emphasis on the latter), review or 222 
reconciliation of medicines and the management of repeat prescriptions. If the 223 
savings reported in the September to December period were consistent throughout 224 
the year, this would equate to an annual saving of 1,884 GP appointments, a saving 225 
of an additional 2,309 hours that GPs in Dudley currently devote to medication 226 
review/reconciliation and the management of repeat prescribing, and financial 227 
savings totalling £354,643.  228 
 229 
Total annual savings (i.e. savings attributable to the interventions of PBPs detailed in 230 
Table 1 and the savings attributable to the transference of activity away from GPs to 231 
PBPs detailed in Table 2) attributable to PBP activities in Dudley CCG are estimated 232 
at £1,794,462. This equates to a saving of £149,538 per calendar month or £3,052 233 
per GP practice per month. These figures exclude costs related to the provision of 234 
PBPs as these are currently met by the CCG rather than by the practices 235 
themselves. 236 
 237 
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Labour costs attributable to PBP provision for the period April to December 2015 238 
were £234,990. This was comprised of 7,833 hours of PBP input at an average 239 
hourly rate of £30 per hour (the majority of PBPs in Dudley CCG are contractors and 240 
are not directly employed by the CCG). Extrapolating from this figure for 9 months’ 241 
worth of PBP provision, the annual costs of PBP provision can be estimated as 242 
£313,320 comprising of 10,444 hours of PBP activity. In terms of return on 243 
investment (ROI), using the formula ROI = (total savings generated – the costs of 244 
PBP provision)/the costs of PBP provision, the data analysed in this work suggest 245 
that for every £1 invested in PBP provision, savings of £4.73 may be realised (for 246 
every hour of PBP activity costing £30, savings of £141.82 may be realised). 247 
 248 
DISCUSSION 249 
 250 
Over the nine month period for which data were available, PBPs operating in 251 
practices within Dudley CCG identified 23,172 interventions, 95% of which went on 252 
to be implemented within GP practices. The annual financial saving to the CCG 253 
attributable to PBP activity was estimated to be approximately £1.5 million (inclusive 254 
of labour costs). 255 
 256 
The use of PBPs in Dudley predates the NHS England ‘Clinical Pharmacists in 257 
General Practice’ pilot and, as such, the data presented here on the nature and 258 
volume of interventions, and the potential savings attributable to PBP activity may be 259 
some of the first data available in this area. While there is no published plan of 260 
evaluation for the NHS England pilot, the differences in the model adopted by Dudley 261 
CCG – where provision of PBPs is funded centrally and the CCG provides clinical 262 
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and systems leadership, supervision and action planning – and the model adopted in 263 
the NHS England pilot – where funding is delivered directly to the GP practices – 264 
mean that any results which emanate from the NHS England pilot may not be 265 
directly comparable to the results presented in this manuscript. Furthermore, this 266 
study was reliant on data from one English CCG meaning that the results reported 267 
are unlikely to be generalisable across primary care in England.  268 
 269 
Neither patient outcomes nor patient or GP acceptability of the PBP programme 270 
were explored in this study. While training was provided to PBPs to promote the 271 
consistent coding of activity data, no assessment of potential inter-PBP variability in 272 
coding was made. Perhaps the most notable limitation of this study concerns the 273 
assumptions and extrapolations that have been included in this manuscript. The 274 
validity of such assumptions and the reliability of such extrapolations is difficult to 275 
accurately assess and figures reliant on such extrapolations should be treated with 276 
an appropriate degree of caution.  277 
 278 
PBPs identified a number of different types of intervention and a large majority of all 279 
types of identified intervention were completed by GP practices within the study 280 
period. This suggests that the interventions proposed by PBPs are valued as either 281 
clinically or financially beneficial (or both) by GPs. Data on PBP time spent at each 282 
GP practice were not available but it is plausible that the variance in the number of 283 
completed interventions between GP practices is a function of the amount of PBP 284 
time spent at each practice. 285 
 286 
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Using the assumptions and extrapolations detailed in the results, the PBP 287 
programme in Dudley as currently delivered may generate total savings in excess of 288 
£1.5 million per annum. Specific evidence from general practice in England is lacking 289 
but previous work has suggested that pharmacist involvement in general practice 290 
may help to control expenditure.(6,7) Whilst the absence of specific patient outcomes 291 
from the dataset makes an assessment of cost-efficiency of the Dudley CCG PBP 292 
programme impossible, the estimated return on investment from PBP provision 293 
provides promising early indications that the programme can assist the CCG in 294 
meeting the efficiency savings demanded of all NHS organisations and may also 295 
support ongoing workforce development in primary care. 296 
 297 
It is recommended that longitudinal data monitoring continues and that such data are 298 
routinely analysed to ensure that the PBP programme in Dudley (and PBP 299 
programmes elsewhere) is meeting its aims and continues to offer a beneficial return 300 
on investment. Such monitoring would also increase the number of observations 301 
which would in turn provide greater insight as to the validity of the assumptions and 302 
improve the accuracy of the extrapolations contained in this manuscript. An 303 
assessment of the reasons for variability in the number of interventions per 304 
population between GP practices and whether this variability is justifiable should be 305 
conducted. Greater focus should also be placed on examining the effect of PBP 306 
interventions on patient outcomes. The case for this, given the volumes in which they 307 
are conducted, is perhaps strongest for medication reviews, 308 
 309 
Further qualitative work should be conducted to add depth to the quantitative data 310 
presented here. Such work will be useful in establishing the perceptions of GPs, 311 
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PBPs and patients regarding this emerging role and may be able to identify potential 312 
areas of improvement in terms of service delivery. Given the absence of evidence 313 
supporting pharmacist activity in general practice, it is imperative that a robust 314 
assessment (e.g. a randomised controlled trial) of the effectiveness and cost-315 
effectiveness of PBPs in improving patient outcomes is undertaken. 316 
 317 
CONCLUSIONS 318 
 319 
In this initial review of data emanating from the Dudley CCG PBP programme, the 320 
high completion rate of interventions identified by PBPs indicates that PBPs are able 321 
to deliver interventions which are valued by GPs in high volume. In doing so, PBPs 322 
were able to generate not inconsiderable financial returns on investment. Financial 323 
savings were accrued as a result of both the interventions suggested by PBPs and 324 
by the transference of activity away from ‘higher cost’ GPs to ‘lower cost’ PBPs. 325 
 326 
This is an emerging field of practice for pharmacists and, as such, evidence 327 
regarding all aspects of said practice is lacking. As PBP activity in Dudley predates 328 
the introduction of NHS England’s ‘Clinical Pharmacists in General Practice Pilot’, 329 
the data presented in this manuscript may be some of the first data available in this 330 
area. Further work, ideally coordinated at the national level, is recommended to 331 
explore stakeholder perceptions of PBPs and their activities, and to examine the 332 
effectiveness and cost-effectiveness of PBPs in improving outcomes at both patient 333 
and system level. Such work is vital if this emerging model is to become embedded 334 
in the English NHS.  335 
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Table 1: Interventions and savings by type of PBP activity, April-December 2015 383 
(excluding savings attributable to the transference of activity away from GPs to 384 
practice-based pharmacists) 385 
 386 
 
Number of 
interventions 
Savings resulting from 
completed interventions 
(£) 
Activity Suggested 
Completed 
(%) 
Total 
Per 
intervention 
Medication reviews1 4453 4413 (99) 125566 28 
Other 4563 4349 (95) 133771 31 
Planned changes to medication/QIPP 3986 3789 (95) 355491 94 
Repeat prescribing & waste management 1894 1883 (99) 34143 18 
Clinic 1708 1691 (99) 37226 22 
Managing long term conditions (LTCs) 1767 1668 (94) 65275 39 
Review of hospital discharge letters 1514 1514 (100) 10327 7 
Audit 1857 1311 (71) 93184 71 
Appliance/homecare2 335 327 (98) 19003 58 
Wound care 272 265 (97) 3744 14 
Involvement in specific campaigns 262 203 (77) 29972 148 
Specials reviews 160 140 (88) 160534 1147 
Review of hospital outpatient letters 128 128 (100) 10979 86 
Drug monitoring and review of test results 120 120 (100) 0 0 
Medication reconciliation3 77 77 (100) 320 4 
Managing high risk drugs 53 53 (100) 305 6 
Hospital admissions for patients with LTCs4 9 9 (100) 0 0 
Quality Premium5 6 6 (100) 0 0 
Triage & management of minor ailments 5 5 (100) 24 5 
Input to multidisciplinary team meetings 3 3 (100) 0 0 
Total 23172 21954 (95) 1079864 49 
1For patients with LTCs conducted using the Dudley Medication Review template 
2Appliance Contractor and homecare including the prescribing of sip feeds and appliances 
3In patients transitioning from secondary to primary care 
4Interventions to reduce hospital admissions as a result of medication in patients with LTCs 
5Contribution to CCG locally agreed Quality Premium focussed on increasing hypertension diagnoses 
and increasing the number of patients diagnosed with hypertension with a blood pressure of <140/90 
mmHg 
  387 
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Table 2: GP time and financial savings attributable to transferral of activity away 388 
from GPs to practice-based pharmacists, September-December 2015 389 
 390 
Activity 
Number of GP 
appointments saved 
GP time saved 
(hrs) 
Financial savings resulting 
(£) 
Patient consultations 628 122.51 276322 
Medicines 
review/reconciliation 
- 272.9 381993 
Repeat prescription 
management 
- 374.2 523833 
Total 628 769.6 118214 
1Based on the average length of a surgery consultation being 11.7 minutes as established by the GP 
Workload Survey 2006/07 and reported in Unit Costs of Health and Social Care 2015 by the Personal 
Social Services Research Unit at the University of Kent (8) 
2Based on the unit cost of a patient contact lasting 11.7 minutes being £44 as reported in Unit Costs 
of Health and Social Care 2015 (8) 
3Based on the unit costs of one hour of GMS activity being £140 as reported in Unit Costs of Health 
and Social Care 2015 (8) 
 391 
  392 
Dudley clinical pharmacists in general practice 
19 
 
FOOTNOTES 393 
 394 
1“Independent prescribers are practitioners responsible and accountable for the 395 
assessment of patients with previously undiagnosed or diagnosed conditions and for 396 
decisions about the clinical management required, including prescribing.”(10) 397 
 398 
2Patient list size was unavailable for 2 of the 49 practices. This figure is based on the 399 
47 practices for which patient list size was available. 400 
 401 
3All medication reviews were conducted in line with the Dudley Medication Review 402 
Best Practice Guidelines.(11) 403 
  404 
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GLOSSARY 405 
 406 
CCG – Clinical commissioning group; statutory NHS bodies responsible for the 407 
planning and commissioning of health care services for their local area. 408 
 409 
NHS England – An executive non-departmental public body of the Department of 410 
Health which leads the National Health Service in England. 411 
 412 
QIPP – Quality, Innovation, Productivity and Prevention; a large scale programme 413 
devised by the Department of Health to drive improvements in quality of care in the  414 
NHS whilst realising considerable efficiency savings. 415 
 416 
Specials – “Specials are unlicensed medicinal products manufactured in the UK for 417 
human use which have been specially prepared to meet a prescription ordered for 418 
individual patients without the need for the manufacturer to hold a marketing 419 
authorisation for the medicinal product concerned”.(12) 420 
